Ecobiotics- A Novel Approach to Recurrent C. difficile infections
February 23, 2016
Hosted by Nancy C. Caralla
This episode introduces Seres Therapeutics, a leading microbiome therapeutics company, which recently published in the Journal of Infectious Diseases positive results from an open-label Phase 1b/2 study of SER-109 for the treatment of patients with recurrent C. difficile infections (CDI). Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current therapeutic approaches. Ecobiotics are ecological compositions of beneficial organisms that are designed to reestablish a healthy microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.
This interview will include forward-looking statements on Seres Therapeutics current expectations and projections about future events. These statements are based upon current beliefs, expectations and assumptions, and are subject to a number of important risks and uncertainties, including those set forth in Seres Therapeutics filings with the SEC, many of which are difficult to predict. Actual results may differ materially from such statements. The information included in this interview is provided only as of the date of this interview, and Seres Therapeutics undertakes no obligation to update any forward-looking statements stated in this interview on account of new information, future events, or otherwise, except as required by law. Seres Therapeutics has provided financial support to the C Diff Foundation.
C. diff. Spores and More
Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.
Nancy C. Caralla
Nancy C. Caralla, a three time C. diff. survivor, healthcare professional, and now dedicated to “Raising C. diff. Awareness” worldwide. Through the experiences is why we are so passionate raising C. diff. awareness. The C Diff Foundation was brought to fruition in November 2012 with a mission to educate and advocate for C. diff. infection prevention, treatment, and environmental safety worldwide. We now join the many successful hosts and programs on VoiceAmerica to deliver life-saving information through our program; “C. diff. Spores and More.”